The European Union remains a "powerhouse of innovation" for biotech and pharma, but mostly looks the the US for funding, according to a new report from BioPharm Insight.
Fuelling the growth of EU Pharma and Biotech states that
- Although trials have dropped by 24% since 2010, sector innovation is high, led by innovations in oncology drugs, neurological agents and gene therapy treatments.
- Deal activity is up in 2015 to date, with increasing interest from European investors; however, three out of top five IPOs listed outside the EU.
- Deeper pools of capital and specialist investors are key factors attracting biotech and pharma to US for funding.
- EU biotechs are exploring a wide spectrum of funding opportunities, including crowdfunding, grant funding and secondary listings.
Copies of the report can be obtained by contacting pressenquiries@mergermarketgroup.com
